Angiogenesis Inhibitors and Hypertension: Clinical Aspects
The aim of the study is to find simple clinical and laboratory parameters to predict the development of hypertension and to elucidate the mechanism of hypertension during treatment with the tyrosine kinase inhibitor Sunitinib.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Angiogenesis Inhibitors and Hypertension: Clinical Aspects|
Blood and urine samples
|Study Start Date:||August 2007|
|Study Completion Date:||December 2009|
Inhibition of angiogenesis with antibodies against vascular endothelial growth factor (VEGF) and VEGF receptor antagonists has become an established treatment for cancer. An unanticipated side effect of angiogenesis inhibitors is the development of hypertension. The pathogenesis of this hypertension is unknown. Not all patients will develop hypertension. However, it is not known which patient will and which patient will not develop hypertension.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00511511
|Rotterdam, Netherlands, 3015 CE|
|Principal Investigator:||A. H. van den Meiracker, MD, PhD||Erasmus Medical Center|